Seminars in Hematology
Volume 45 , Pages S50-S57 , April 2008

Blood-Induced Joint Disease: The Confluence of Dysregulated Oncogenes, Inflammatory Signals, and Angiogenic Cues

References 

  1. Mannucci PM. Hemophilia and related bleeding disorders: A story of dismay and success. Hematology Am Soc Hematol Educ Program 1-9. 2002;
  2. Ahlberg A. Haemophilia in Sweden (VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B). Acta Orthop Scand Suppl. 1965;(suppl 77):3–132
  3. Aronstam A, Rainsford SG, Painter MJ. Patterns of bleeding in adolescents with severe haemophilia A. Br Med J. 1979;1:469–470
  4. Marion J, Favre-Gilly J, Picault CH, Gauthier G. Discovery of hemophilia at the time of intervention for villous synovitis of the elbow. Hemostase. 1965;5:69–71
  5. König F. Diseases of the joint in bleeders, especially with regard to the diagnosis. Clin Orthop Relat Res. 1967;52:5–11
  6. Salavec M. [Joint manifestations in hemophilia]. Vnitr Lek. 1970;16:21–28
  7. Procházka J, Rocek V, Krc C, Vyslouzil F, Procek J. [Joint lesions in hemophilia: clinical-x-ray study]. Vnitr Lek. 1975;21:240–248
  8. Holstein J. [Joint changes in hemophilia in the roentgenogram: Survey of 30 cases]. Dtsch Gesundheitsw. 1960;15:2470–2476
  9. Johnson JB, Davis TW, Bullock WH. Bone and joint changes in hemophilia; a long-term study in twelve Negro subjects. Radiology. 1954;63:64–71
  10. Nuss R, Kilcoyne RF, Geraghty S, Shroyer AL, Rosky JW, Mawhinney S, et al. MRI findings in haemophilic joints treated with radiosynoviorthesis with development of an MRI scale of joint damage. Haemophilia. 2000;6:162–169
  11. Nuss R, Kilcoyne RF, Rivard GE, Murphy J. Late clinical, plain x-ray and magnetic resonance imaging findings in haemophilic joints treated with radiosynoviorthesis. Haemophilia. 2000;6:658–663
  12. Handelsman JE. The knee joint in hemophilia. Orthop Clin North Am. 1979;10:139–173
  13. Wen FQ, Jabbar AA, Chen YX, Kazarian T, Patel DA, Valentino LA. c-myc proto-oncogene expression in hemophilic synovitis: In vitro studies of the effects of iron and ceramide. Blood. 2002;100:912–916
  14. Hakobyan N, Kazarian T, Jabbar AA, Jabbar KJ, Valentino LA. Pathobiology of hemophilic synovitis I: Overexpression of mdm2 oncogene. Blood. 2004;104:2060–2064
  15. Hoots WK, Rodriguez N, Boggio L, Valentino LA. Pathogenesis of haemophilic synovitis: Clinical aspects. Haemophilia. 2007;13(suppl 3):4–9
  16. Valentino LA, Hakobyan N, Rodriguez N, Hoots WK. Pathogenesis of haemophilic synovitis: Experimental studies on blood-induced joint damage. Haemophilia. 2007;13(suppl 3):10–13
  17. Rodriguez-Merchan EC. Haemophilic synovitis: Basic concepts. Haemophilia. 2007;13(suppl 3):1–3
  18. Rodríguez-Merchán EC. Effects of hemophilia on articulations of children and adults. Clin Orthop Relat Res. 1996;7–13
  19. Pollmann H, Richter H, Ringkamp H, Jürgens H. When are children diagnosed as having severe haemophilia and when do they start to bleed? (A 10-year single-centre PUP study). Eur J Pediatr. 1999;158(suppl 3):S166–S170
  20. Fischer K, van der Bom JG, Mauser-Bunschoten EP, Roosendaal G, Prejs R, de Kleijn P, et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood. 2002;99:2337–2341
  21. Manco-Johnson MM, Abshire TC, Brown D, Buchanan GR, Cohen AR, DiMichele D, et al. Initial results of a randomized, prospective trial of prophylaxis to prevent joint disease in young children with factor VIII (FVIII) deficiency. In: Presented at the American Society of Hematology 47th Annual Meeting and Exposition, Atlanta, GA, December 12-13. 2005;
  22. van Dijk K, Fischer K, van der Bom JG, Grobbee DE, van den Berg HM. Variability in clinical phenotype of severe haemophilia: The role of the first joint bleed. Haemophilia. 2005;11:438–443
  23. Pain in hemophilia. Lancet. 1973;1:931–932
  24. Lusher JM. Assessment of response to treatment and design of clinical trials. Prog Clin Biol Res. 1984;150:167–179
  25. Choinière M, Melzack R. Acute and chronic pain in hemophilia. Pain. 1987;31:317–331
  26. Rattray B, Nugent DJ, Young G. Rofecoxib as adjunctive therapy for haemophilic arthropathy. Haemophilia. 2005;11:240–244
  27. Soucie JM, Cianfrini C, Janco RL, Kulkarni R, Hambleton J, Evatt B, et al. Joint range-of-motion limitations among young males with hemophilia: Prevalence and risk factors. Blood. 2004;103:2467–2473
  28. von Mackensen S. Quality of life and sports activities in patients with haemophilia. Haemophilia. 2007;13(suppl 2):38–43
  29. Fischer K, van der Bom JG, van den Berg HM. Health-related quality of life as outcome parameter in haemophilia treatment. Haemophilia. 2003;9(suppl 1):75–82
  30. Poonnoose PM, Thomas R, Keshava SN, Cherian RS, Padankatti S, Pazani D, et al. Psychometric analysis of the Functional Independence Score in Haemophilia (FISH). Haemophilia. 2007;13:620–626
  31. Remor E, Arranz P, Quintana M, Villar A, Jiménez-Yuste V, Diaz JL, et al. Psychometric field study of the new haemophilia quality of life questionnaire for adults: The ‘Hemofilia-QoL. ' Haemophilia. 2005;11:603–610
  32. Royal S, Schramm W, Berntorp E, Giangrande P, Gringeri A, Ludlam C, et al. Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia. 2002;8:44–50
  33. MASAC: Medical and Scientific Advisory Council Recommendation Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding). MASAC Recommendation 170 National Hemophilia Foundation; 2006;
  34. World Federation of Hemophilia: Guidelines for the management of hemophilia, 2005. 2005 http://www.wfh.org/2/docs/Publications/Diagnosis_and_Treatment/Gudelines_Mng_Hemophilia.pdfAccessed February 7, 2008
  35. Berntorp E, Boulyjenkov V, Brettler D, Chandy M, Jones P, Lee C, et al. Modern treatment of haemophilia. Bull World Health Organ. 1995;73:691–701
  36. Hoots WK, Nugent DJ. Evidence for the benefits of prophylaxis in the management of hemophilia A. Thromb Haemost. 2006;96:433–440
  37. Pipe SW, Valentino LA. Optimizing outcomes for patients with severe haemophilia A. Haemophilia. 2007;13(suppl 4):1–16
  38. Löfqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients—A long-term follow-up. J Intern Med. 1997;241:395–400
  39. Nilsson IM. Experience with prophylaxis in Sweden. Semin Hematol. 1993;30(suppl 2):16–19
  40. Nilsson IM. Is haemophilia prophylaxis achievable in the context of self-sufficiency?. Blood Coagul Fibrinolysis. 1994;5(suppl 4):S71–S75
  41. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med. 1992;232:25–32
  42. Nilsson IM, Blombäck M, Ahlberg A. Our experience in Sweden with prophylaxis on haemophilia. Bibl Haematol. 1970;34:111–124
  43. Nilsson IM, Hedner U, Ahlberg A. Haemophilia prophylaxis in Sweden. Acta Paediatr Scand. 1976;65:129–135
  44. Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357:535–544
  45. Centers for Disease Control and Prevention: Report on the Universal Data Collection Program 7 (No. 1):17. 2005;
  46. Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia. 2001;7:392–396
  47. Petrini P. Identifying and overcoming barriers to prophylaxis in the management of haemophilia. Haemophilia. 2007;13(suppl 2):16–22
  48. Mejia-Carvajal C, Hakobyan N, Enockson C, Valentino LA. The impact of joint bleeding and synovitis on physical ability and joint function in a murine model of haemophilic synovitis. Haemophilia. 2008;14:119–126
  49. Hakobyan N, Kazarian T, Valentino LA. Synovitis in a murine model of human factor VIII deficiency. Haemophilia. 2005;11:227–232
  50. Valentino LA, Hakobyan N. Histological changes in murine haemophilic synovitis: A quantitative grading system to assess blood-induced synovitis. Haemophilia. 2006;12:654–662
  51. Lin J, Hakobyan N, Valentino LA. Digital analysis of vascularity in hemophilic synovitis. Blood. 2006;108:4070;abstr
  52. Gazitt Y, Reddy SV, Alcantara O, Yang J, Boldt DH. A new molecular role for iron in regulation of cell cycling and differentiation of HL-60 human leukemia cells: Iron is required for transcription of p21(WAF1/CIP1) in cells induced by phorbol myristate acetate. J Cell Physiol. 2001;187:124–135
  53. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs (The Orthopaedic Outcome Study Group). J Intern Med. 1994;236:391–399
  54. Hakobyan N, Enockson C, Cole AA, Sumner DR, Valentino LA: Experimental haemophilic arthropathy in a mouse model of a massive hemarthrosis: Gross, radiological, and histological changes. Haemophilia (in press)
  55. Hilliard P, Funk S, Zourikian N, Bergstrom BM, Bradley CS, McLimont M, et al. Hemophilia joint health score reliability study. Haemophilia. 2006;12:518–525
  56. Manco-Johnson MJ, Nuss R, Funk S, Murphy J. Joint evaluation instruments for children and adults with haemophilia. Haemophilia. 2000;6:649–657
  57. Manco-Johnson MJ, Pettersson H, Petrini P, Babyn PS, Bergstrom BM, Bradley CS, et al. Physical therapy and imaging outcome measures in a haemophilia population treated with factor prophylaxis: Current status and future directions. Haemophilia. 2004;10(suppl 4):88–93
  58. Roosendaal G, Vianen ME, Marx JJ, van den Berg HM, Lafeber FP, Bijlsma JW. Blood-induced joint damage: A human in vitro study. Arthritis Rheum. 1999;42:1025–1032
  59. Eger W, Schumacher BL, Mollenhauer J, Kuettner KE, Cole AA. Human knee and ankle cartilage explants: Catabolic differences. J Orthop Res. 2002;20:526–534

 STATEMENT OF CONFLICT OF INTEREST: Leonard Valentino has received grants/research support from Novo Nordisk, Baxter Bioscience, Bayer Healthcare, GlaxoSmithKline, Wyeth, and CSL Behring. He has also served as an advisory board member/consultant for Novo Nordisk, Baxter Bioscience, Wyeth, and CSL Behring, and has served on a speakers' bureau or as a faculty member for Novo Nordisk and Wyeth. Narine Hakobyan has received grant funding from CSL Behring Foundation. Candace Enockson declares no conflict of interest.

PII: S0037-1963(08)00057-7

doi: 10.1053/j.seminhematol.2008.03.017

Seminars in Hematology
Volume 45 , Pages S50-S57 , April 2008

Article Tools

* Image Usage & Resolution